MaxCyte, Inc. MaxCyte, Inc. - MXCR - Total Voting Rights

MaxCyte

31/05/2017 16:30

RNS Number : 7231G

MaxCyte, Inc.

31 May 2017

MaxCyte, Inc.

("MaxCyte" or the "Company")

Total Voting Rights

Maryland, USA -31 May 2017: MaxCyte (LSE: MXCT, MXCR) announces that, following an exercise of options, 22,435 new shares of common stock of $0.01 each in the Company (the "Common Stock") were issued from the blocklisting facility granted 5 May 2017.

The total issued stock capital of the Company has consequently increased to 50,836,962 Common Stock. There is no Common Stock held in treasury.Therefore, the total number of voting rights in the Company is 50,836,962. Stockholders in the Company may use this figure as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the capital of the Company.

The number of unrestricted shares of Common Stock trading under the symbol 'MXCT' is 43,561,962 and the number of restricted shares of Common Stock trading under the symbol 'MXCR' is 7,275,000. The number of Common Stock capable of being issued under the blocklisting facility is 977,565Common Stock.

- ENDS -

For further information please contact:

MaxCyte
+1 301 944 1660
Doug Doerfler, Chief Executive Officer
Ron Holtz, Chief Financial Officer
Nominated Adviser and Broker
Panmure Gordon
Freddy Crossley (Corporate Finance)
Fabien Holler
Duncan Monteith
Tom Salvesen (Corporate Broking)
+44 (0) 20 7886 2500
Financial PR Advisor
Consilium Strategic Communications
+44 (0)203 709 5700
maxcyte@consilium-comms.com
Mary-Jane Elliott
Chris Welsh
Lindsey Neville


About MaxCyte

MaxCyte (LSE: MXCT), is a US-based global company dedicated to driving the acceleration of the discovery, development, manufacturing and commercialisation of next-generation, cell-based medicines. The Company provides its patented, high-performance cell engineering platform to biopharmaceutical partners engaged in drug discovery and development, biomanufacturing, and cell therapy, including gene editing and immuno-oncology. With its robust delivery platform, MaxCyte's team of scientific experts helps its partners to unlock their product potential and solve problems. This platform allows for the engineering of nearly all cell types, including human primary cells, with any molecule, at any scale. It also provides a high degree of consistency and minimal cell disturbance, thereby facilitating rapid, large-scale, clinical and commercial grade cell engineering in a non-viral system and with low-toxicity concerns. The Company's cell-engineering platform is FDA-accredited, providing MaxCyte's customers and partners with an established regulatory path to commercialise cell-based medicines.

For more information, visit http://www.maxcyte.com/

This information is provided by RNS

The company news service from the London Stock Exchange

  END

TVROKDDPBBKDFPN